Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q2 2020 · 10-Q
Revenue$267.19K$267.19K+96.9% vs Q2 2019 Net Income-$128.70M-$128.70MN/M vs Q2 2019 EPS Diluted-$0.83-$0.83N/M vs Q2 2019 Operating Income-$33,180,898N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$27,187,069N/M Margins · derivedOperating margin-12418.6%+8367.2 pt vs Q2 2019
Net margin-48169.7%−26509.3 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 10, 2020 · 41 d after period end